Journal of Oncology

Bioinformatics in Cancer and Immune Microenvironment


Publishing date
01 Jul 2022
Status
Published
Submission deadline
04 Mar 2022

Lead Editor
Guest Editors

1Neonatal Department, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China

2Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China

3Department Pain Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, China

4University of Verona Medical School, Verona, China


Bioinformatics in Cancer and Immune Microenvironment

Description

Tumor cells do not exist in isolation in the microenvironment of malignancy but rather in a diverse ecosystem that includes not only heterogeneous tumor cell clones, but also normal cell types like fibroblasts, vasculature, and a large pool of immune cells at various stages of activation and differentiation. As a consequence, there is now a complicated interaction of different cellular signaling pathways with the immune cell component influencing cancer development and therapeutic response. To capitalize on potential therapeutic and biomarker findings, it is challenging and time-consuming to thoroughly and systematically characterize these different cell types from diverse tumor samples using immunohistochemistry. We have now entered an era of digital cancer treatment, fueled by the increasing availability of omics technologies, in which varied and global molecular profiling may drive therapeutic discovery and predict immunotherapy responses. Computationally extracting cell-type specific information directly from bulk tumors is one promising answer to this problem. The benefit of using bioinformatics to predict accurate immune signatures from bulk native tumor tissue is that the functional intracellular and intercellular transcriptome profiles are preserved, whereas when purified immune cells are isolated from native tissue, the molecular profiles will have inherently different patterns. Such in silico methods are beneficial because they may capture cell-type specific characteristics as well as cell-cell interactions at the tissue system level.

Predicting tumor patterns accurately and completely is a significant problem to solve, especially considering the effectiveness of immunotherapeutic medication therapy for many human malignancies. This is particularly difficult for subgroups of closely similar immune cell phenotypes with modest gene expression variations but significant functional differences. It will be very beneficial to use bioinformatics strategies to profile the tumor immune landscape because it will allow us to systematically profile one immune cell population's patterns and immune cell networks in tumors with higher resolution, which will aid in the discovery of immune-modulatory drugs.

The goal of this Special Issue is to bring together original research and review articles that will help researchers better understand the complex interactions that exist between tumors, immune cells, and the microenvironment, as well as the discovery of new biomarkers and molecular targets in various cancers.

Potential topics include but are not limited to the following:

  • Bioinformatics research into new cancer diagnosis and treatment methods based on the immune microenvironment
  • Immunological, gene regulatory, and pathophysiological mechanisms involved in carcinogenesis
  • The crosstalk between immune and nonimmune cells in the tumor microenvironment
  • Drug target discovery and targeted drug design
  • Therapeutic strategies that modulate the immune response
  • Meta-analysis to identify the function of tumor microenvironment in cancer

Articles

  • Special Issue
  • - Volume 2023
  • - Article ID 9807856
  • - Retraction

Retracted: IL2RB Is a Prognostic Biomarker Associated with Immune Infiltrates in Pan-Cancer

Journal of Oncology
  • Special Issue
  • - Volume 2022
  • - Article ID 5722599
  • - Research Article

Expression Patterns of Necroptosis-Related Genes: Predicting Prognosis and Immunotherapeutic Effects in Cutaneous Melanoma

Dong Dong | Wei Wang | ... | Tianyi Liu
  • Special Issue
  • - Volume 2022
  • - Article ID 6792850
  • - Research Article

A Novel Thrombosis-Related Signature for Predicting Survival and Drug Compounds in Glioblastoma

Wen-Jing Zeng | Yu-Fang Cao | ... | Quan Cheng
  • Special Issue
  • - Volume 2022
  • - Article ID 6725570
  • - Research Article

A Pancancer Study of PIEZO1 as a Prognosis and Immune Biomarker of Human Tumors

Yunhui Wu | Jingying Zhang | ... | Xin Yao
  • Special Issue
  • - Volume 2022
  • - Article ID 3982539
  • - Research Article

A Pan-Cancer Analysis of UBE2S in Tumorigenesis, Prognosis, Pathway, Immune Infiltration and Evasion, and Therapy Response from an Immune-Oncology Perspective

Haili Bao | Yi Luo | ... | Zhiren Fu
  • Special Issue
  • - Volume 2022
  • - Article ID 8016102
  • - Research Article

HOXC6 Regulates the Epithelial-Mesenchymal Transition through the TGF-β/Smad Signaling Pathway and Predicts a Poor Prognosis in Glioblastoma

Sun Eryi | Li Zheng | ... | Chen Bo
  • Special Issue
  • - Volume 2022
  • - Article ID 4269733
  • - Research Article

Identification of MBOAT2 as an Unfavorable Biomarker Correlated with KRAS Activation and Reduced CD8+ T-Cell Infiltration in Pancreatic Cancer

Zhenchong Li | Hongkai Zhuang | ... | Baohua Hou
  • Special Issue
  • - Volume 2022
  • - Article ID 2043880
  • - Research Article

[Retracted] IL2RB Is a Prognostic Biomarker Associated with Immune Infiltrates in Pan-Cancer

Guangyao Li | Yandong Wang | Ya Cheng
  • Special Issue
  • - Volume 2022
  • - Article ID 7715689
  • - Research Article

Cytotoxic Evaluation, Molecular Docking, and 2D-QSAR Studies of Dihydropyrimidinone Derivatives as Potential Anticancer Agents

Reem Altaf | Humaira Nadeem | ... | Faisal Raza
  • Special Issue
  • - Volume 2022
  • - Article ID 6452636
  • - Research Article

Identification of Cancer-Associated Fibroblast Subtype of Triple-Negative Breast Cancer

Maoli Wang | Ruifa Feng | ... | Xiqing Li
Journal of Oncology
 Journal metrics
See full report
Acceptance rate6%
Submission to final decision136 days
Acceptance to publication68 days
CiteScore3.900
Journal Citation Indicator-
Impact Factor-

We have begun to integrate the 200+ Hindawi journals into Wiley’s journal portfolio. You can find out more about how this benefits our journal communities on our FAQ.